Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented, "In August, SMMT's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments